secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001821586-25-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab
-------------------------------------------------------------------------

- Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.
- R&D expenses $60.6M (up from $49.8M) driven by trial ramp-up and BLA prep.
- Phase 2 LEDA PPP: 64% mean PPPASI reduction, 39% PPPASI75 at week 16; no approved therapies.
- VELA-TEEN interim: 46% HiSCR75 in adolescent HS at week 16 (n=11); BLA submission Q3/Q4 2026.
- FDA Type B meeting Dec 15, 2025 to discuss SLK in HS evidence for BLA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/0001821586-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/mnlk-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001821586-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer